EGFR mutations in salivary gland carcinoma
Author Information
Author(s): Dahse R, Kosmehl H
Primary Institution: HELIOS Clinics Erfurt, Institute of Pathology
Hypothesis
EGFR-activating mutations in salivary gland carcinoma might occur, making EGFR a potential molecular target for therapy.
Conclusion
The presence of EGFR-activating mutations in salivary gland carcinomas may identify patients who could benefit from tyrosine kinase inhibitor therapies.
Supporting Evidence
- Two drug-sensitizing EGFR exon 19 deletion mutations were identified in salivary gland carcinoma.
- EGFR mutations are known to correlate with better responses to certain cancer therapies.
- Salivary gland carcinomas have a poor prognosis and limited response to traditional chemotherapies.
Takeaway
Scientists found that some patients with salivary gland cancer have a specific mutation that could help them respond better to certain medicines.
Methodology
DNA was isolated from microdissected tumor areas and screened for common EGFR-activating mutations using allele-specific PCR assays.
Limitations
The study only included a small number of patients and focused on specific mutations.
Participant Demographics
16 males and 9 females with a median age of 61 years.
Statistical Information
Confidence Interval
1.4–27.5%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website